Sanofi India Ltd.
•Add ratio to table
ABOUT
AI Sector View
AI GENERATEDHealthcare
This stance relies on proxies and positioning because no direct pharma-export or healthcare operating series exists in the dataset. The depreciated currency at 95.23 (Sep/26) can support export earnings, inflation at 4.45% (Jul/26) is manageable for a defensive sector, and consumer spending remains large at INR 44743 billion (Jun/26). Strong FPI inflow of INR 10620 crore over 3 months to 2026-08-31 from INR -11381 crore in the prior 3 months adds a real sector-specific tailwind, but confidence stays capped because the fundamental drivers are indirect proxies.
PROS
- Company is almost debt free
- Company has a healthy return on capital (ROCE) of 59.3%
- Company has a good return on equity (ROE) track record: 3 Years ROE 43.2%
- Strong cash generation - operating cash flow backs reported profits (CFO/PAT 0.93x)
- Company has been maintaining a healthy dividend payout of 65.1%
CONS
- Receivables are growing faster than sales - a possible quality concern
- Recent results are weak - TTM profit is down 57.9% versus prior year
- Stock is trading at 17.8x its book value
- Recurring exceptional / one-off items are inflating headline profit
- Inventory has been piling up - inventory days up from 68 to 103
* The pros and cons are machine generated based on quantitative rules.
Peer comparison
| Name | ||||||||||
|---|---|---|---|---|---|---|---|---|---|---|
| SUNPHARMA | 1842.00 | 36.54 | 441957.50 | 0.87 | 2901.23 | 26.53 | 15299.88 | 10.98 | 19.11 | 28.81 |
| DIVISLAB | 9326.00 | 84.64 | 247576.00 | 0.32 | 902.00 | 65.50 | 3080.00 | 27.80 | 21.51 | 40.75 |
| TORNTPHARM | 4975.00 | 86.76 | 189233.01 | 0.76 | 566.00 | 3.28 | 4921.00 | 57.32 | 19.27 | 33.81 |
| ZYDUSLIFE | 1119.50 | 24.74 | 111670.55 | 0.09 | 990.20 | -34.90 | 8017.00 | 23.97 | 21.39 | 24.54 |
| CIPLA | 1365.00 | 32.72 | 110272.68 | 0.95 | 785.55 | -39.18 | 7119.28 | 4.13 | 16.00 | 16.73 |
| LAURUSLABS | 1970.35 | 97.37 | 106460.42 | 0.10 | 362.07 | 123.94 | 2026.31 | 29.10 | 18.20 | 31.50 |
| DRREDDY | 1161.00 | 30.07 | 96906.38 | 0.69 | 435.60 | -69.10 | 8099.80 | -5.21 | 13.75 | 10.63 |
| AUROPHARMA | 1675.45 | 25.97 | 96401.69 | 0.24 | 10320.30 | 1152.16 | 91503.50 | 1062.96 | 12.76 | 20.54 |
| LUPIN | 2096.00 | 17.34 | 95842.92 | 0.86 | 1416.98 | 16.01 | 8276.89 | 34.28 | 28.86 | 29.59 |
| MANKIND | 2277.00 | 46.04 | 94050.37 | 0.04 | 574.09 | 29.12 | 4030.59 | 12.89 | 13.24 | 26.30 |
| GLENMARK | 2416.90 | 37.94 | 68210.88 | 0.10 | 482.83 | 927.88 | 4018.48 | 31.35 | 20.35 | 20.03 |
| SANOFI | 3079.85 | 17.16 | 7093.09 | 3.99 | 91.30 | -93.37 | 514.90 | 9.74 | 55.46 | 26.08 |
Quarterly Results
Consolidated Figures in Rs. Crores / View Standalone
| Jun 2023 | Sep 2023 | Dec 2023 | Mar 2024 | Jun 2024 | Sep 2024 | Dec 2024 | |
|---|---|---|---|---|---|---|---|
| 515 | 491 | 469 | 732 | 464 | 524 | 515 | |
| 393 | 377 | 370 | 514 | 348 | 404 | 397 | |
| Operating Profit | 122 | 114 | 100 | 219 | 116 | 120 | 118 |
| OPM % | 23.62% | 23.13% | 21.23% | 29.89% | 24.96% | 22.84% | 22.98% |
| 16 | 11 | 9 | -20 | -14 | 2 | 14 | |
| Interest | 1 | 0 | 0 | 0 | 0 | 0 | 0 |
| Depreciation | 9 | 9 | 9 | 10 | 9 | 9 | 10 |
| Profit before Tax | 127 | 115 | 99 | 188 | 92 | 113 | 122 |
| Tax % | 36.37% | 29.67% | 29.81% | 27.49% | 25.95% | 27.00% | 25.29% |
| Net Profit | 1,229 | 1,519 | 1,377 | 137 | 1,032 | 82 | 91 |
| 53.37 | 65.95 | 30.26 | 59.31 | 44.81 | 35.69 | 39.64 |
Profit & Loss
Consolidated Figures in Rs. Crores / View Standalone
| Dec 2004 | Dec 2023 | Dec 2024 | TTM | |
|---|---|---|---|---|
| 743 | 1,996 | 2,013 | 2,235 | |
| 511 | 1,509 | 1,523 | 1,662 | |
| Operating Profit | 231 | 487 | 490 | 573 |
| OPM % | 31.14% | 24.40% | 24.35% | 25.62% |
| 27 | 80 | -21 | -18 | |
| Interest | 0 | 2 | 2 | 2 |
| Depreciation | 19 | 36 | 37 | 38 |
| Profit before Tax | 239 | 528 | 431 | 515 |
| Tax % | 34.75% | 31.01% | 27.28% | 26.59% |
| Net Profit | 156 | 365 | 314 | 378 |
| EPS | 67.71 | 262.13 | 179.70 | — |
| Dividend Payout % | 23.63% | 63.71% | 65.11% | — |
COMPOUNDED SALES GROWTH
- 10 Years:
- —
- 5 Years:
- —
- 3 Years:
- —
COMPOUNDED PROFIT GROWTH
- 10 Years:
- —
- 5 Years:
- —
- 3 Years:
- —
STOCK PRICE CAGR
- 10 Years:
- -3%
- 5 Years:
- -18%
- 3 Years:
- -24%
- 1 Year:
- -39%
RETURN ON EQUITY
- 10 Years:
- —
- 5 Years:
- —
- 3 Years:
- 43%
- Last Year:
- 36%
Balance Sheet
Consolidated Figures in Rs. Crores / View Standalone
| Dec 2004 | Dec 2023 | Dec 2024 | |
|---|---|---|---|
| Equity Capital | 23 | 23 | 23 |
| 431 | 924 | 768 | |
| 20 | 14 | 14 | |
| Trade Payables | 40 | 292 | 406 |
| 91 | 3,451 | 3,468 | |
| Total Liabilities | 606 | 4,703 | 4,679 |
| 167 | 315 | 312 | |
| Capital Work in Progress | 3 | 13 | 18 |
| 111 | 664 | 500 | |
| 93 | 132 | 230 | |
| Cash & Bank | 180 | 406 | 295 |
| 51 | 3,173 | 3,324 | |
| Total Assets | 606 | 4,703 | 4,679 |
Cash Flows
Consolidated Figures in Rs. Crores / View Standalone
| Dec 2004 | Dec 2023 | Dec 2024 | |
|---|---|---|---|
| 85 | 230 | 462 | |
| Cash from Investing | 2 | 38 | -19 |
| Cash from Financing | -42 | -878 | -392 |
| 45 | -610 | 50 |
Ratios
Consolidated Figures in Rs. Crores / View Standalone
| Dec 2004 | Dec 2023 | Dec 2024 | |
|---|---|---|---|
Documents
Corporate disclosures, annual reports, credit ratings, and concall transcripts
2026-09-08 - Disclosure under Regulation 30 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 ( SEBI (LODR) Regulations )
2026-08-31 - Disclosure under Regulation 30 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 Receipt of Show Cause Notice from GST Authorities
2026-08-13 - Please find enclosed intimation under Regulation 30 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015
2026-08-11 - Please find enclosed intimation under Regulation 30 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015
2026-08-10 - Sanofi India Limited has informed the Exchange about Transcript of Investor / Analysts Call.
2026-08-06 - Sanofi India Limited has informed the Exchange about Link of Video Recording of Investor / Analysts Call
2026-08-05 - Sanofi India Limited has informed the Exchange about copies of Newspaper Publication of Financial Results for the quarter and half year ended 30th June 2026
2026-08-05 - Sanofi India Limited has informed the Exchange about Investor / Analysts Call - Presentation
2026-08-04 - Sanofi India Limited has informed the Exchange about Intimation Under Regulation 30(5) Of the Listing Regulations
News
Recent coverage and analyst commentary for SANOFI
Loading news…
AI Stock Analyst
Sanofi India Ltd.
Sign in to Chat with AI
Log in with your 5nance account to ask institutional questions about performance, financials, and outlook.
✨ Sign In to ChatFree 5nance Account

